Table 3.
Characteristics of naïve-treated patients versus treated patients.
| Variables | Naïve | Treated | ||||
|---|---|---|---|---|---|---|
| Any TDR | Susceptible | p | Any ADR | Susceptible | p | |
| Agemedian ± IQR | 41.2 (31.7–49) | 40.4 (31–48) | 0.47 | 41.2 (34–48) | 40 (33–46) | 0.0225 |
| Gender(number (%) | 0.281 | 0.018 | ||||
| Male | 228/2288 (9.9, 8.6.11.1) | 91.1% | 631/983 (64.1, 61.1–67.1) | 39% | ||
| Female | 109/1233 (8.8, 7.2–10.3) | 90.1% | 345/593 (58.1, 54.1–62) | 37% | ||
| Countries(number (%) | 0.1614 | 0.416 | ||||
| Angola | 21/212 (9.9, 5.88–13.9) | 90.1% | 92/144 (63.8, 55.9–71.6) | 36.2% | ||
| Brazil | 14/164 (8.5, 4.23–12.7)) | 91.5% | 27/42 (64, 49.4–78.5) | 36% | ||
| Cape Verde | 14/186 (7.6, 3.79–11.4)) | 92.4% | 72/107 (67.2, 58.3–76.1) | 32.8% | ||
| Guinea-Bissau | 24/307 (7.8, 4.8–10.8) | 92.2% | 49/95 (51.5, 41.4–61.5) | 48.5% | ||
| Mozambique | 16/92 (17.4, 9.6- 25.1) | 82.6% | 17/29 (58.6, 40.6–76.5) | 41.4% | ||
| Sao Tome and Principe | 4/56 (7.1, 3.7–13.8) | 92.9% | 12/20 (60, 38.5–81.4) | 40% | ||
| Portugal | 249/2535 (9.8, 8.6–10.9) | 90.2% | 711/1152 (61.7, 58.9–64.5) | 38.3% | ||
| Subtype(number (%) | 0.005 | 0.02 | ||||
| 02_AG | 30/365 (8.2, 4.2–10.7) | 92.5% | 61/120 (50.2, 41.2–59.1) | 51.2% | ||
| A | 7/144(4.9, 1.3–8.2) | 95.2% | 16/28 (57, 38.6–75.3) | 43% | ||
| B | 141/1278 (11, 9.8–13.2) | 88.5% | 385/570 (67.2, 63.3–71) | 32.8% | ||
| C | 36/261 (13.7, 9.6–18) | 86.2% | 54/92 (58.6, 48.5–68.6) | 41.4% | ||
| D | 3/31(9.6, 0.7–19.9) | 90.4% | 8/11 (72.7, 46.3–99) | 27.3% | ||
| F1 | 17/153 (11, 6–16) | 89% | 18/31 (58, 40.6–75.3) | 42% | ||
| G | 57/843 (6.8, 5.1.8.5) | 93.2% | 317/537 (59, 54.8–63.1) | 41% | ||
| Recombinants | 51/464 (10.9, 8.1–13.2) | 89.3% | 119/195 (61, 54.1–67.8) | 39.8% | ||
| VLmedian ± IQR | 4.6 (4.0 – 5.1) | 4.7 (4.2– 5.4) | 0.011 | 4.1 (3.5 – 4.7) | 4.5 (3.8–5.2) | <0.0001 |
| CD4median ± IQR | 388 (209 – 549) | 345 (129–493) | 0.024 | 291 (118 – 420) | 287 (125–386) | 0.452 |